Search

Smith & Nephew PLC

Open

1,247.5 -0.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1245

Max

1257.5

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

30.012

21.746

EPS

0.429

Dividendrendement

3.1

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+16.59% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.10%

4.48%

Volgende Winsten

2 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.5B

10B

Vorige openingsprijs

1247.94

Vorige sluitingsprijs

1247.5

Smith & Nephew PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 jan 2026, 23:11 UTC

Winsten

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7 jan 2026, 22:55 UTC

Belangrijke Marktbewegers

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7 jan 2026, 21:39 UTC

Belangrijke Marktbewegers

Raytheon Down Following Trump Post Criticizing Company

7 jan 2026, 20:13 UTC

Belangrijke Marktbewegers

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7 jan 2026, 20:03 UTC

Belangrijke Marktbewegers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7 jan 2026, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 jan 2026, 23:46 UTC

Marktinformatie

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7 jan 2026, 23:42 UTC

Acquisities, Fusies, Overnames

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7 jan 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7 jan 2026, 23:29 UTC

Acquisities, Fusies, Overnames

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7 jan 2026, 22:48 UTC

Marktinformatie

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7 jan 2026, 22:46 UTC

Winsten

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7 jan 2026, 22:45 UTC

Winsten

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 jan 2026, 22:42 UTC

Winsten

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7 jan 2026, 22:41 UTC

Winsten

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7 jan 2026, 22:41 UTC

Winsten

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7 jan 2026, 22:40 UTC

Belangrijke Marktbewegers

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7 jan 2026, 22:31 UTC

Marktinformatie

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7 jan 2026, 22:22 UTC

Marktinformatie

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7 jan 2026, 22:01 UTC

Marktinformatie

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 jan 2026, 21:46 UTC

Marktinformatie

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7 jan 2026, 21:22 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7 jan 2026, 21:18 UTC

Acquisities, Fusies, Overnames

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7 jan 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7 jan 2026, 20:29 UTC

Acquisities, Fusies, Overnames

AbbVie Near Deal for Revolution Medicines -- Update

7 jan 2026, 20:27 UTC

Marktinformatie

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7 jan 2026, 19:58 UTC

Marktinformatie

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7 jan 2026, 19:48 UTC

Belangrijke Marktbewegers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Smith & Nephew PLC Prognose

Koersdoel

By TipRanks

16.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,464.33 GBX  16.59%

Hoogste 1,650 GBX

Laagste 1,290 GBX

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

5

Buy

4

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat